Cidel Asset Management Inc. Buys Shares of 279,490 AstraZeneca PLC $AZNCF

Cidel Asset Management Inc. bought a new stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 279,490 shares of the company’s stock, valued at approximately $55,095,000. AstraZeneca comprises 3.0% of Cidel Asset Management Inc.’s investment portfolio, making the stock its 3rd largest position.

A number of other hedge funds have also recently made changes to their positions in the stock. Hughes Financial Services LLC purchased a new stake in shares of AstraZeneca in the 4th quarter worth approximately $34,000. Bell Investment Advisors Inc bought a new position in AstraZeneca during the 1st quarter valued at approximately $39,000. Fairscale Capital LLC purchased a new position in AstraZeneca during the fourth quarter valued at $37,000. Aventus Investment Advisors Inc. purchased a new position in AstraZeneca during the first quarter valued at $46,000. Finally, Mascoma Wealth Management LLC bought a new stake in AstraZeneca in the fourth quarter worth $46,000. 40.87% of the stock is owned by institutional investors.

AstraZeneca Price Performance

OTCMKTS AZNCF opened at $187.10 on Wednesday. AstraZeneca PLC has a 12 month low of $122.26 and a 12 month high of $195.00. The stock’s fifty day moving average price is $187.10 and its 200-day moving average price is $186.15.

AstraZeneca Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.